RecruitingNCT07541469

Rezdiffra Pregnancy and Lactation Registry

A Phase 4, Decentralized Observational Registry to Evaluate the Safety in Women With NASH and Their Infants Exposed to REZDIFFRA™ (Resmetirom) During Pregnancy and/or Lactation

Sponsor

Madrigal Pharmaceuticals, Inc.

Enrollment

10 participants

Start Date

Mar 4, 2026

Study Type

OBSERVATIONAL

Conditions

MASH - Metabolic Dysfunction-Associated Steatohepatitis

Summary

To evaluate pregnancy and clinical outcomes in women with NASH and their infants after exposure to Rezdiffra at any time during pregnancy and/or lactation.

Eligibility

Sex: FEMALE

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Rezdiffra for people with mash - metabolic dysfunction-associated steatohepatitis. The study is currently recruiting participants at 1 location. People eligible for this study include women.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.